Related Experiment Video
Updated: Jun 29, 2025
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.6K
[Molecular testing of prostate cancer: timing, methods and consequences]
Gunhild von Amsberg1,2, Finn-Ole Paulsen1
1Onkologisches Zentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Aktuelle Urologie
|March 27, 2024
Summary
Molecular testing is increasingly important for understanding metastatic prostate cancer. This review covers current molecular diagnostics and their impact on targeted therapies, including hereditary predispositions.
Area of Science:
- Oncology
- Genetics
- Molecular Pathology
Background:
- Metastatic prostate cancer is complex, with treatments typically based on tumor extent and patient factors, not molecular details.
- Molecular pathology is underutilized in current clinical decision-making for prostate cancer.
- Advances in next-generation sequencing (NGS) are improving molecular testing and understanding of prostate cancer development.
Conclusions:
- Molecular pathology should be integrated into prostate cancer treatment decisions.
- Understanding molecular alterations is key to developing effective targeted therapies.
- Future prostate cancer management will likely involve more personalized, molecularly-guided approaches.
